HCC
Conditions
Interventions
Experimental group:Carrelizumab + traditional Chinese medicine exposure
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, gender unlimited; 2. HCC confirmed by histology/cytology or imaging meets the clinical diagnostic criteria of the 2019 edition of the Guidelines for Diagnosis and Treatment of Primary Liver Cancer; 3. No systemic antitumor therapy was received within the first six months of enrollment; 4. At least one measurable lesion (MRECIST); 5.BCLC staging: A-B; 6.Child-Pugh score <=9 points; 7.ECOG physical status score 0~2 points; 8. For women of childbearing age or male patients whose sexual partners are women of childbearing age, effective contraceptive measures should be taken throughout the treatment period and within 6 months after the last medication; 9. Sign the written informed consent, and can comply with the protocol and family consent to participate in the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. A history of other tumors within 1.5 years; 2. Previous histological/cytological diagnosis of fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc.; 3. Patients with a large number of cancerous ascites and brain metastases; 4. Main portal vein tumor thrombus also involved contralateral portal vein branch; 5. Local treatment, including hyperthermia, TACE and radiotherapy, was given within two months before enrollment; 6. Patients with liver cancer who plan to undergo liver transplantation or surgical resection; 7. Severe infections in active stage or poorly controlled clinically; 8. Grade II heart failure, centrifuge ischemia and uncontrollable arrhythmia; 9. Any hemorrhage event of esophageal or fundus varices caused by portal hypertension in the past 6 months or any life-threatening bleeding event in the past 3 months; 10. Diseases that affect the efficacy of oral drugs, such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.; 11. Have contraindications to microwave hyperthermia; Have a history of PD-1 antibody allergy; 12. Pregnant and lactating women; 13. Subjects the investigator deems unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;disease control rate;overall survival;adverse event rate;Probability of serious adverse events; | — |
Countries
China
Contacts
Public ContactLi Ping
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed